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Background
ARVT (antiretroviral treatment) improved the prognosis
of patients with HIV (Human Immunodeficiency Virus)
infection. Antiretroviral drugs may be responsible for HR
(hypersensitivity reactions) varying in severity, clinical
manifestations and frequency.
Methods
We report a case of a 47-year-old woman, with diagnosis
of HIV infection since 2009 (HLA B5701 negative) that
started ARVT in 2011. On the 2nd day of treatment with
Tenofovir, Emtricitabine and Nevirapine she developed
pruritic exanthema and palpebral edema. Two weeks later
the Infecciologist discontinued ARVT and prescribed AH
(antihistamines) and CS (oral corticosteroids) with
symptoms resolution. One month later treatment with
Tenofovir and Emtricitabine was restarted in association
with Darunavir and Ritonavir. There was a reproducible
reaction on the 2nd day of treatment. After the reaction
subsided, the patient restarted Darunavir and Ritonavir in
association with Abacavir and Lamivudine. On the
2nd day she developed palpebral edema and discontinued
ARVT once again. She was then referred to our Drug
Allergy Clinic for suspected hypersensitivity to ARVT.
Results
PT (patch tests) with the suspected drugs were positive for
Emtricitabine and Tenofovir and revealed only erythema
to Lamivudine. PT performed in 7 controls were negative.
Negative DPT (drug provocation test) with Darunavir,
Ritonavir and Abacavir were followed by home treatment
with no adverse reactions. DPT with Nevirapine was
positive (pruritic exanthema and palpebral edema). DPT
with an alternative drug, Raltegravir, was negative.
Conclusion
HR to Darunavir, Ritonavir and Abacavir were excluded,
so the patient restarted treatment with these drugs. Since
combined therapy with 3 or more drugs is recommended
to avoid viral resistance, Raltegravir was introduced to
complete therapeutic regimen. HR to Nevirapine was
confirmed and HR to Emtricitabine and Tenofovir was
considered probable based on positive PT. We admit
a possible cross-reactivity with Lamivudine.
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